AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24717711 — intervention group
Group type: COMPARATOR
Intervention: Control (no fluoride therapy)
Number of subjects: 25
Study 22307566 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed soy isoflavones (PTIG-2535), 6-month intervention
Number of subjects: 126
Study 22307566 — intervention group
Group type: COMPARATOR
Intervention: Placebo, 6-month intervention
Number of subjects: 126
Study 22307566 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy isoflavones
Number of subjects: 126
Study 22307566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 19166770 — intervention group
Group type: EXPERIMENTAL
Intervention: Apical patency maintained during shaping procedures with a #10 K‐file (n = 115)
Number of subjects: 300
Study 19166770 — intervention group
Group type: EXPERIMENTAL
Intervention: Apical patency maintained
Number of subjects: 300
Study 19166770 — intervention group
Group type: COMPARATOR
Intervention: Apical patency not maintained (n = 121)
Number of subjects: 300
Study 17454195 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH‐analog (GnRH‐a)
Number of subjects: 29
Study 17454195 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (CHT) without GnRH‐a
Number of subjects: 29
Study 15164912 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial sleepiness scale based on cartoon faces
Number of subjects: 835
Study 12215327 — intervention group
Group type: EXPERIMENTAL
Intervention: HP-hMG
Number of subjects: 781
Study 12215327 — intervention group
Group type: COMPARATOR
Intervention: Recombinant FSH
Number of subjects: 781
Study 10100275 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum ICAM-1 levels in patients with ALL
Number of subjects: 54
Study 10100275 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum ICAM-1 levels in patients with Hodgkin's disease (HD)
Number of subjects: 54
Study 10100275 — intervention group
Group type: COMPARATOR
Intervention: Serum ICAM-1 levels in patients with acute myeloid leukemia (AML)
Number of subjects: 54
Study 10100275 — intervention group
Group type: COMPARATOR
Intervention: Serum ICAM-1 levels in patients with non-Hodgkin's lymphoma (NHL)
Number of subjects: 54
Study 10100275 — intervention group
Group type: COMPARATOR
Intervention: Serum ICAM-1 levels in patients with Burkitt's lymphoma (BL)
Number of subjects: 54
Study 10100275 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum ICAM-1 levels in ALL patients in complete remission
Number of subjects: 54
Study 10100275 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum ICAM-1 levels in HD patients in complete remission
Number of subjects: 54
Study 10100275 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of serum ICAM-1 levels with high ESR in HD patients
Number of subjects: 54
Study 10100275 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum sICAM-1 levels
Number of subjects: 54
Study 10100275 — intervention group
Group type: EXPERIMENTAL
Intervention: Determination of serum level and/or tumor tissue expression of ICAM-1 in HD and ALL
Number of subjects: 54
Study 8901350 — intervention group
Group type: EXPERIMENTAL
Intervention: Deaf
Number of subjects: 222
Study 8901350 — intervention group
Group type: COMPARATOR
Intervention: Blind
Number of subjects: 222
Study 8901350 — intervention group
Group type: COMPARATOR
Intervention: No sensory disability
Number of subjects: 222
Study 2057991 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer program predicting warfarin dosage adjustments
Number of subjects: 50
Study 2057991 — intervention group
Group type: COMPARATOR
Intervention: Skilled professional care by an anticoagulation nurse-specialist
Number of subjects: 50
Study 6144301 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxmetidine
Number of subjects: 83
Study 6144301 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 83
Study 6144301 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 83
Study 6144301 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsmokers
Number of subjects: 83
Study 6144301 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers with healed ulcers
Number of subjects: 83
Study 6144301 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers with non-healed ulcers
Number of subjects: 83
Study 6144301 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing cigarette consumption
Number of subjects: 83
Study 6144301 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients smoking nine cigarettes a day or less
Number of subjects: 83
Study 30039182 — intervention group
Group type: EXPERIMENTAL
Intervention: real transcranial direct current stimulation (tDCS)
Number of subjects: 16
Study 30039182 — intervention group
Group type: COMPARATOR
Intervention: sham stimulation
Number of subjects: 16
Study 29304199 — intervention group
Group type: EXPERIMENTAL
Intervention: monovalent high‐dose type 2‐specific IPV (mIPV2HD)
Number of subjects: 0
Study 29304199 — intervention group
Group type: COMPARATOR
Intervention: standard trivalent IPV
Number of subjects: 0
Study 29304199 — intervention group
Group type: EXPERIMENTAL
Intervention: mIPV2HD
Number of subjects: 0
Study 29304199 — intervention group
Group type: EXPERIMENTAL
Intervention: mOPV2
Number of subjects: 0
Study 26620651 — intervention group
Group type: EXPERIMENTAL
Intervention: Football training group (FTG)
Number of subjects: 57
Study 26620651 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 57
Study 25675650 — intervention group
Group type: EXPERIMENTAL
Intervention: Uniform MDT (UMDT)
Number of subjects: 0
Study 25675650 — intervention group
Group type: COMPARATOR
Intervention: Regular MDT (RMDT)
Number of subjects: 0
Study 23306000 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir (50 mg once daily)
Number of subjects: 822
Study 23306000 — intervention group
Group type: COMPARATOR
Intervention: Raltegravir (400 mg twice daily)
Number of subjects: 822
Study 23306000 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Number of subjects: 822
Study 23306000 — intervention group
Group type: COMPARATOR
Intervention: Raltegravir
Number of subjects: 822
Study 20940636 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-second heavy resisted sprint on ice
Number of subjects: 11
Study 20940636 — intervention group
Group type: COMPARATOR
Intervention: Control condition (rest)
Number of subjects: 11
Study 19058332 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant enteral supplement
Number of subjects: 21
Study 16837793 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH therapy at the dose of 0.23 mg/kg/week s.c.
Number of subjects: 12
Study 12802751 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pleconaril
Number of subjects: 1363
Study 12802751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1363
Study 10650298 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive 2-month exercise training program
Number of subjects: 25
Study 10650298 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 25
Study 9554153 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-feeding (at least once daily)
Number of subjects: 767
Study 9554153 — intervention group
Group type: COMPARATOR
Intervention: Artificial feeding (control group)
Number of subjects: 767
Study 9554153 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-feeding
Number of subjects: 767
Study 1527286 — intervention group
Group type: EXPERIMENTAL
Intervention: Anistreplase (APSAC) 30 U/2 to 5 min with aspirin (160 mg/day) and intravenous heparin
Number of subjects: 325
Study 1527286 — intervention group
Group type: COMPARATOR
Intervention: Alteplase (rt-PA) 100 mg/3 h with aspirin (160 mg/day) and intravenous heparin
Number of subjects: 325
Study 1527286 — intervention group
Group type: EXPERIMENTAL
Intervention: Anistreplase (APSAC)
Number of subjects: 325
Study 1527286 — intervention group
Group type: COMPARATOR
Intervention: Alteplase (rt-PA)
Number of subjects: 325
Study 31948255 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy intervention (daily exercises aimed at the foot arch)
Number of subjects: 12
Study 31948255 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 12
Study 29800784 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine plus hydrochlorothiazide
Number of subjects: 702
Study 29800784 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine plus perindopril
Number of subjects: 702
Study 29800784 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril plus hydrochlorothiazide
Number of subjects: 702
Study 25884235 — intervention group
Group type: EXPERIMENTAL
Intervention: Ward-based psychological intervention
Number of subjects: 51
Study 25884235 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 51
Study 24895806 — intervention group
Group type: EXPERIMENTAL
Intervention: HD-NBI
Number of subjects: 113
Study 24895806 — intervention group
Group type: COMPARATOR
Intervention: HD-WL
Number of subjects: 113
Study 22921291 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice training group (n=14)
Number of subjects: 48
Study 22921291 — intervention group
Group type: COMPARATOR
Intervention: Nontraining control group (n=34)
Number of subjects: 48
Study 21084610 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity in the parahippocampal cortex during encoding
Number of subjects: 0
Study 21084610 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity in several regions of the PFC and the hippocampus during encoding
Number of subjects: 0
Study 21084610 — intervention group
Group type: EXPERIMENTAL
Intervention: Rostrolateral PFC activity during encoding
Number of subjects: 0
Study 18796517 — intervention group
Group type: EXPERIMENTAL
Intervention: Genistein aglycone (54 mg daily)
Number of subjects: 138
Study 18796517 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 16317127 — intervention group
Group type: EXPERIMENTAL
Intervention: High-iron rice (3.21 mg/kg Fe)
Number of subjects: 192
Study 16317127 — intervention group
Group type: COMPARATOR
Intervention: Control rice (0.57 mg/kg Fe)
Number of subjects: 192
Study 12866745 — intervention group
Group type: EXPERIMENTAL
Intervention: Penta E locus
Number of subjects: 0
Study 12866745 — intervention group
Group type: EXPERIMENTAL
Intervention: Penta E, FGA, D18S51, D8S1179
Number of subjects: 0
Study 12866745 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical parameters calculated
Number of subjects: 0
Study 12866745 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall method
Number of subjects: 0
Study 10390425 — intervention group
Group type: EXPERIMENTAL
Intervention: Proventil‐HFA (100, 200, and 400 micrograms)
Number of subjects: 18
Study 10390425 — intervention group
Group type: COMPARATOR
Intervention: Ventolin‐CFC (100, 200, and 400 micrograms)
Number of subjects: 18
Study 8893437 — intervention group
Group type: EXPERIMENTAL
Intervention: Biocompatible osteoconductive polymer
Number of subjects: 115
Study 8893437 — intervention group
Group type: COMPARATOR
Intervention: Iliac bone graft
Number of subjects: 115
Study 7961550 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 0
Study 7961550 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 0
Study 2958282 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (20 mg/2 ml)
Number of subjects: 15
Study 2958282 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (500 micrograms/2 ml)
Number of subjects: 15
Study 2958282 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (5 mg/2 ml)
Number of subjects: 15
Study 2958282 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 15
Study 2958282 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (10 mg in 4 ml) after placebo (4 ml saline)
Number of subjects: 15
Study 30687806 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxing acupressure
Number of subjects: 288
Study 30687806 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulating acupressure
Number of subjects: 288
Study 30687806 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 288
Study 30687806 — intervention group
Group type: EXPERIMENTAL
Intervention: Both acupressure groups (relaxing and stimulating)
Number of subjects: 288
Study 27377675 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-virus, lab-generated PCR panel
Number of subjects: 127
Study 27377675 — intervention group
Group type: COMPARATOR
Intervention: FilmArray PCR panel
Number of subjects: 127
Study 27377675 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 127
Study 26881924 — intervention group
Group type: EXPERIMENTAL
Intervention: Pafuramidine (100 mg orally BID for 5 days)
Number of subjects: 113
Study 26881924 — intervention group
Group type: COMPARATOR
Intervention: Pentamidine (standard therapy for 7 days)
Number of subjects: 113
Study 26881924 — intervention group
Group type: EXPERIMENTAL
Intervention: Pafuramidine (10 days)
Number of subjects: 113
Study 26881924 — intervention group
Group type: COMPARATOR
Intervention: Pentamidine (5 days)
Number of subjects: 113
Study 26881924 — intervention group
Group type: EXPERIMENTAL
Intervention: Pafuramidine (5 days)
Number of subjects: 113
Study 23078581 — intervention group
Group type: EXPERIMENTAL
Intervention: FT antireflux UIA (Group A)
Number of subjects: 49
Study 23078581 — intervention group
Group type: COMPARATOR
Intervention: Refluxing direct elliptical UIA (Group B)
Number of subjects: 49
Study 21291437 — intervention group
Group type: EXPERIMENTAL
Intervention: Child FIRST
Number of subjects: 157
Study 21291437 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 157
Study 19400851 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil (10 mg)
Number of subjects: 49
Study 19400851 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50 mg)
Number of subjects: 49
Study 16455787 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrarectal sphere or latex balloon at 8, 6, or 4 cm from the anal verge
Number of subjects: 24
Study 16455787 — intervention group
Group type: COMPARATOR
Intervention: Control patients (asymptomatic women)
Number of subjects: 24
Study 16455787 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental patients (women with symptoms of difficult defecation)
Number of subjects: 24
Study 15242465 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 573
Study 15242465 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 573
Study 15242465 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 573
Study 15242465 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRIs (overall)
Number of subjects: 573
Study 15242465 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 573
Study 11431764 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyloric traumamyoplasty (n = 43)
Number of subjects: 100
Study 11431764 — intervention group
Group type: COMPARATOR
Intervention: Fredet-Ramstedt pyloromyotomy (n = 57)
Number of subjects: 100
Study 11431764 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyloric traumamyoplasty
Number of subjects: 100
Study 11431764 — intervention group
Group type: COMPARATOR
Intervention: Fredet-Ramstedt pyloromyotomy
Number of subjects: 100
Study 10556611 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech sounds (Finnish vowel /a/ with two different glottal excitations)
Number of subjects: 0
Study 10556611 — intervention group
Group type: COMPARATOR
Intervention: Tone sounds (sinusoidal stimulus)
Number of subjects: 0
Study 10556611 — intervention group
Group type: EXPERIMENTAL
Intervention: Vowels with varying perceptual quality (from 'soft' /a/ to 'pressed' /A')
Number of subjects: 0
Study 7644653 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic patient-instruction (API) device
Number of subjects: 128
Study 7644653 — intervention group
Group type: COMPARATOR
Intervention: Technologist-performed patient instruction
Number of subjects: 128
Study 2665559 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 2665559 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.32 g alcohol/kg body weight
Number of subjects: 31
Study 2665559 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.65 g alcohol/kg body weight
Number of subjects: 31
Study 2665559 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.81 g alcohol/kg body weight
Number of subjects: 31
Study 779949 — intervention group
Group type: COMPARATOR
Intervention: 5-FU 400 mg/m2 weekly intravenously
Number of subjects: 294
Study 779949 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU 400 mg/m2 i.v. weekly plus methyl-CCNU 175 mg/m2 orally every 6 weeks
Number of subjects: 294
Study 31125079 — intervention group
Group type: EXPERIMENTAL
Intervention: menthol Tobacco Heating System 2.2 (mTHS)
Number of subjects: 160
Study 31125079 — intervention group
Group type: COMPARATOR
Intervention: menthol cigarette
Number of subjects: 160
Study 31125079 — intervention group
Group type: COMPARATOR
Intervention: smoking abstinence
Number of subjects: 160
Study 30402705 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced bowel preparation (r‐CTC)
Number of subjects: 1286
Study 30402705 — intervention group
Group type: COMPARATOR
Intervention: Full bowel preparation (f‐CTC)
Number of subjects: 1286
Study 29141858 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra 100 mg daily subcutaneous injections for 12 weeks
Number of subjects: 60
Study 29141858 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra 100 mg daily subcutaneous injections for 2 weeks
Number of subjects: 60
Study 29141858 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 29141858 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra 12-week
Number of subjects: 60
Study 29141858 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra 2-week
Number of subjects: 60
Study 25579196 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist-ankle acupuncture and ginger moxibustion
Number of subjects: 60
Study 25579196 — intervention group
Group type: COMPARATOR
Intervention: Tropisetron hydrochloride and dexamethasone
Number of subjects: 60
Study 23940237 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) 5 ppm for 7 to 21 days
Number of subjects: 792
Study 23940237 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 792
Study 19926748 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchoreversibility
Number of subjects: 544
Study 19926748 — intervention group
Group type: EXPERIMENTAL
Intervention: Large changes in FVC
Number of subjects: 544
Study 19926748 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in FEV(1)
Number of subjects: 544
Study 19926748 — intervention group
Group type: EXPERIMENTAL
Intervention: FVC improvements
Number of subjects: 544
Study 18041047 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug therapies for schizophrenic patients
Number of subjects: 0
Study 16888462 — intervention group
Group type: COMPARATOR
Intervention: 6% carbohydrate drink (CHO)
Number of subjects: 10
Study 16888462 — intervention group
Group type: COMPARATOR
Intervention: 2% protein added to a 6% carbohydrate drink (CHO‐PRO)
Number of subjects: 10
Study 16888462 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonenergetic sweetened placebo (PLAC)
Number of subjects: 10
Study 14636807 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention schools
Number of subjects: 41
Study 14636807 — intervention group
Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 41
Study 11091928 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart-rate feedback
Number of subjects: 54
Study 11091928 — intervention group
Group type: COMPARATOR
Intervention: No feedback
Number of subjects: 54
Study 2263306 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemonucleolysis with chymopapain
Number of subjects: 69
Study 2263306 — intervention group
Group type: COMPARATOR
Intervention: Operated patients
Number of subjects: 69
Study 509865 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiological and laboratory investigations
Number of subjects: 67
Study 509865 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiological investigations
Number of subjects: 67
Study 30238417 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydrogen peroxide (HP6)
Number of subjects: 54
Study 30238417 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% hydrogen peroxide (HP15)
Number of subjects: 54
Study 30238417 — intervention group
Group type: COMPARATOR
Intervention: Both HP6 and HP15
Number of subjects: 54
Study 29137502 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine solution applied to umbilical cord stumps
Number of subjects: 200
Study 29137502 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group not explicitly mentioned)
Number of subjects: 200
Study 25727275 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based education module plus a sample genomics consent form (n = 65)
Number of subjects: 134
Study 25727275 — intervention group
Group type: COMPARATOR
Intervention: Sample genomics consent form only (n = 69)
Number of subjects: 134
Study 25727275 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based education module
Number of subjects: 134
Study 24270900 — intervention group
Group type: EXPERIMENTAL
Intervention: parecoxib sodium 40 mg (Group P, n=40)
Number of subjects: 120
Study 24270900 — intervention group
Group type: EXPERIMENTAL
Intervention: tramadol 2 mg/kg (Group T, n=40)
Number of subjects: 120
Study 24270900 — intervention group
Group type: COMPARATOR
Intervention: isotonic saline (Group S, n=40)
Number of subjects: 120
Study 22129522 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus pravastatin (n=3866)
Number of subjects: 7832
Study 22129522 — intervention group
Group type: COMPARATOR
Intervention: Diet alone (n=3966)
Number of subjects: 7832
Study 19445659 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine plus aripiprazole
Number of subjects: 100
Study 19445659 — intervention group
Group type: COMPARATOR
Intervention: Clozapine plus haloperidol
Number of subjects: 100
Study 19445659 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine plus aripiprazole and haloperidol
Number of subjects: 100
Study 17217436 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV7 (n = 23)
Number of subjects: 47
Study 17217436 — intervention group
Group type: COMPARATOR
Intervention: PPV23 (n = 24)
Number of subjects: 47
Study 17217436 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PCV7 and PPV23
Number of subjects: 47